Phase 2 N=22 Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
Prostate Cancer
Primary: To Evaluate the Efficacy of Bevacizumab Plus Erlotinib — 9; 1; 2; 7 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=33 A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-24 Hours on Day 14 — 1.827; 1.664 Liters
Phase 2 N=148 Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
Estrogen Receptor-positive Breast Cancer · Progesterone Receptor-positive Breast Cancer · Recurrent Breast Cancer
Primary: Clinical Benefit Rate — 44; 41 percentage of participants
Phase 2 N=78 Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Response to Intravenous Canakinumab and Oral Methotrexate (MTX) Compared to MTX Alone as Determined by 50% Improvement in Symptoms According to the American College of…
Phase 2 N=45 Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Carcinoid Tumors
Primary: Symptom Control (Diarrhea/Flushing) Using a Patient Symptom Diary — 3; 9; 32 participants
Phase 2 N=432 A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)
Gout
Primary: Core Study: Mean Number of Gout Flares Per Participant — 0.5; 0.4; 0.2; 0.4 Gout flares
Phase 2 N=61 A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia
Schizophrenia
Primary: Number of Subjects With an Adverse Events in a One Year Open Label Lurasidone Study — 59 participants
Phase 2 N=22 CEP-701 for PH-negative Myelofibrosis
Leukemia · Myelofibrosis
Primary: Number of Participants With Objective Response — 0; 0; 6 Participants
Phase 2 N=8 Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients
Leukemia · Chronic Myelogenous Leukemia · Chronic Myeloid Leukemia
Primary: Number of Participants With Complete Response — 3 Participants
Phase 2 N=61 Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
Macular Degeneration
Primary: Summary of Adverse Events — 57; 16; 47; 4 participants
Phase 2 N=30 Caffeinol Hypothermia Protocol
Acute Ischemic Stroke
Primary: Number of Participants With Symptomatic Intracerebral Hemorrhage — 0 participants
Phase 2 N=94 Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy
Spinal Muscular Atrophy
Primary: Safety Labs
Phase 2 N=35 Effects of Treating Obstructive Sleep Apnea in Epilepsy
Epilepsy · Sleep Apnea · Obstructive Sleep Apnea
Primary: CPAP Adherence/Tolerance as Measured by Proportion of Nights Used — 0.74; 0.66 proportion of nights used (total nights — p=0.26
Phase 2 N=203 Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
Sickle Cell Disease · Iron Overload · Hemolytic Anemia
Primary: The Number of Participants With Adverse Events (AEs) in the First 24 Weeks of Treatment — 30; 17; 30; 8 participants
Phase 2 N=10 Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
Systemic Mastocytosis
Primary: Number of Participants With Objective Response — 0 Participants